Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SteadyMed Ltd.

Division of United Therapeutics Corp.
www.steadymed.com

Latest From SteadyMed Ltd.

Keeping Track: US FDA Approvals For Ibsrela, Gvoke And Nucala; A BTD For Tepotinib

The latest drug development news and highlights from our US FDA Performance Tracker. 
US FDA Performance Tracker Approvals

Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate

With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.

Deals Commercial

CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due

The European Medicines Agency’s key scientific committee, the CHMP, is deciding whether a raft of new products, including Eli Lilly’s galcanezumab, should be approved for sale across the EU. Sarepta’s appeal of the CHMP’s earlier rejection of its marketing application for Exondys is also slated for a decision.

Europe Drug Review

CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due

The European Medicines Agency’s key scientific committee, the CHMP, is deciding whether a raft of new products, including Eli Lilly’s galcanezumab, should be approved for sale across the EU. Sarepta’s appeal of the CHMP’s earlier rejection of its marketing application for Exondys is also slated for a decision.

Europe Drug Review
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Transdermal
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • SteadyMed Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • United Therapeutics Corp.
  • Senior Management
  • Jonathan M Rigby, Pres. & CEO
    David W Nassif, EVP, CFO
    Robert Zwolinski, SVP, Operations
  • Contact Info
  • SteadyMed Ltd.
    Phone: (925) 272-4999
    2410 Camino Ramon
    Ste. 285
    San Ramon, CA 94583
    USA
UsernamePublicRestriction

Register